GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer

Gilead Sciences, Inc. (GILD) announced positive top-line results from yet another late-stage study on breast cancer drug, Trodelvy (sacituzumab govitecan-hziy).Data from the phase III ASCENT-03 study on Trodelvy showed highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with first-line metastatic triple-negative breast cancer (mTNBC) who are not candidates for checkpoint inhibitors.This is the second positive phase III study in first-line mTN ...